Fig. 15.

Examples of sPLA₂ liposomal targeting in breast cancer. (A) Schematic of the proposed mechanism of action of sPLA₂; oxaliplatin-encapsulating liposomes extravasates from the fenestrated capillaries of tumors where elevated levels of sPLA₂ cause the release of the drug in a localized area. (B) Although the in vivo treatment of sPLA₂-sensitive oxaliplatin-encapsulating liposomes showed an improvement in the survival of nude mice bearing MT-3 xenograft tumors, the skin of the mice exhibited subcutaneous bleeding, and liver sections showed multiple areas of necrosis in hepatocytes, vacuolar degeneration and an acute inflammatory reaction with an accumulation of granulocytes (black arrows). Reprinted with permission from Ref. [214]. Copyright 2017 Elsevier.